Evidence map›Paper›PMID 35681675›Full record

ArticleCancers2022

Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).

Amr Mohamed, Namrata Vijayvergia, Matthew Kurian, Lisa Liu, Pingfu Fu, Satya Das

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Amr MohamedDepartment of Medicine, Division of Hematology and Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0000-0002-6962-3535
Namrata VijayvergiaDepartment of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.ORCID 0000-0001-6469-4759
Matthew KurianDepartment of Medicine, Division of Hematology and Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0000-0003-4015-5261
Lisa LiuDepartment of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.ORCID 0000-0001-7521-9777
Pingfu FuDepartment of Medicine, Division of Hematology and Medical Oncology, University Hospitals, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0000-0002-2334-5218
Satya DasDepartment of Medicine, Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
University Hospitals Seidman Cancer Center · USFox Chase Cancer Center · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

checkpoint inhibitor therapychemotherapyneuroendocrine carcinomanivolumab and ipilimumab

Identifiers

PMID35681675
PMCPMC9179548
OpenAlexW4281685124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.